Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Study of Coprelotamab vs Trastuzumab in Healthy Volunteers
NCT04905667Phase 1Completed
- Sponsor
- Genor Biopharma
- Start
- Nov 2019
- Primary completion
- Sep 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of coprelotamab in HER2-positive breast cancer (2 arms), sponsored by Genor Biopharma. Primary endpoints: Area Under the Serum Concentration-Time Curve From Time Zero to Last Quantifiable Concentration at Day 43, Area Under the Serum Concentration-Time Curve From Time Zero to Infinity at Day 43 and 1 more. Started Nov 2019; status: completed.
02
Drugs
coprelotamab
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT04905667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04905667.